Myelodysplastic Syndromes — Lower-Risk (IPSS-R very low / low / intermediate) · line 2 · Imetelstat (Rytelo) for transfusion-dependent LR-MDS post-ESA failure
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-IMETELSTAT-MDS-LR |
| ID | IND-MDS-LR-2L-IMETELSTAT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MDS-LR |
| Sources | SRC-ESMO-MDS-2021 SRC-IMERGE-PLATZBECKER-2024 SRC-IPSS-M-BERNARD-2022 SRC-NCCN-AML-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L for transfusion-dependent LR-MDS post-ESA failure. Ukraine access barrier dominant. Telomerase inhibition is novel mechanism — monitor emerging long-term safety data (clonal evolution, AML transformation rates).
Used By
Algorithms
ALGO-MDS-LR-2L- ALGO-MDS-LR-2L